A Chinese multicenter, real-world study of PD-L1 inhibitors in extensive stage small cell lung cancer

被引：0

作者：

Peng, J. ^{[1
]}

Meng, R. ^{[2
]}

Liu, X. ^{[3
]}

Zhang, L. ^{[4
]}

Wang, L. ^{[5
]}

Feng, R. ^{[1
]}

Feng, H. ^{[6
]}

Huang, Z. ^{[7
]}

Yao, D. ^{[8
]}

Li, X. ^{[9
]}

Liu, N. ^{[10
]}

Tan, B. ^{[11
]}

Li, S. ^{[12
]}

Yu, J. ^{[1
]}

Meng, X. ^{[1
]}

机构：

[1] Shandong First Med Univ & Shandong Acad Med Sci, Shandong Canc Hosp & Inst, Radiat Oncol, Jinan, Peoples R China

[2] Huazhong Univ Sci & Technol, Canc Ctr Union Hosp, Tongji Med Coll, Union Hosp, Wuhan, Peoples R China

[3] Jinzhou Med Univ, Oncol Dept, Jinzhou, Peoples R China

[4] Hunan Canc Hosp, Thorac Dept, Changsha, Peoples R China

[5] Baotou Canc Hosp, Baotou, Peoples R China

[6] Qingdao Univ, Affiliated Hosp, Qingdao, Peoples R China

[7] Shandong Prov Hosp, Jinan, Peoples R China

[8] Chaoyang Second Hosp, Chaoyang, Peoples R China

[9] Chifeng Municipal Hosp, Chifeng, Inner Mongolia, Peoples R China

[10] Tianjin Med Univ, Canc Inst & Hosp, Tianjin, Peoples R China

[11] Shandong Univ, Qilu Hosp, Radiat Oncol, Jinan, Peoples R China

[12] Zibo Municipal Hosp, Zibo, Peoples R China

来源：

JOURNAL OF THORACIC ONCOLOGY | 2023年 / 18卷 / 04期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

172P

引用

页码：S135 / S135

页数：1

共 50 条

[1] Real-world outcomes in extensive-stage small cell lung cancer with PD-L1 inhibitors in China
Meng, X.
Peng, J.
Li, S.
Feng, H.
Meng, R.
Zhang, L.
Liu, X.
Yu, J.
ANNALS OF ONCOLOGY, 2021, 32 : S1420 - S1421
[2] Real-world outcomes of PD-L1 inhibitors combined with thoracic radiotherapy in the first-line treatment of extensive stage small cell lung cancer
Peng, Jianfeng
Zhang, Lemeng
Wang, Liping
Feng, Hui
Yao, Dongmei
Meng, Rui
Liu, Xiaomei
Li, Xiaohua
Liu, Ningbo
Tan, Bingxu
Huang, Zhaoqin
Li, Shanshan
Meng, Xiangjiao
RADIATION ONCOLOGY, 2023, 18 (01)
[3] Real-world outcomes of PD-L1 inhibitors combined with thoracic radiotherapy in the first-line treatment of extensive stage small cell lung cancer
Jianfeng Peng
Lemeng Zhang
Liping Wang
Hui Feng
Dongmei Yao
Rui Meng
Xiaomei Liu
Xiaohua Li
Ningbo Liu
Bingxu Tan
Zhaoqin Huang
Shanshan Li
Xiangjiao Meng
Radiation Oncology, 18
[4] A real-world study of anlotinib in combination with PD-L1 inhibitors plus chemotherapy as first-line therapy for extensive-stage small cell lung cancer.
Chen, Size
Lin, Yiguang
Song, Minghan
Dong, Jiayi
Lijuan, Shao
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[5] Clinical impact of first-line PD-1 or PD-L1 inhibitors combined with chemotherapy in extensive-stage small cell lung cancer patients: A real-world multicenter propensity score-matched study
Xie, Jingyuan
Chen, Mo
Han, Hedong
Xu, Ke
Qiu, Guihuan
Lin, Xinqing
Song, Yong
Ye, Jinjun
Lv, Tangfeng
Zhan, Ping
THORACIC CANCER, 2023, 14 (15) : 1327 - 1338
[6] The Efficacy and Safety of Anlotinib in Extensive-Stage Small Cell Lung Cancer: A Multicenter Real-World Study
Zheng, Hao-Ran
Jiang, Ai-Min
Gao, Huan
Liu, Na
Zheng, Xiao-Qiang
Fu, Xiao
Zhang, Rui
Ruan, Zhi-Ping
Tian, Tao
Liang, Xuan
Yao, Yu
CANCER MANAGEMENT AND RESEARCH, 2022, 14 : 2273 - 2287
[7] The Efficacy of PD-1/PD-L1 Inhibitors in Patients with Liver Metastasis of Non-Small Cell Lung Cancer: A Real-World Study
Xie, Mingying
Li, Na
Xu, Xiaoling
Xu, Yanjun
Li, Hui
Zhu, Liang
Sheng, Jiamin
Zhou, Zichao
Fan, Yun
CANCERS, 2022, 14 (17)
[8] Comparison of efficacy and safety between PD-1 inhibitors and PD-L1 inhibitors plus platinum-etoposide as first-line treatment for extensive-stage small-cell lung cancer: a multicenter, real-world analysis
Yanrong Wang
Lingling Li
Jia Hu
Yan Zhao
Huan Yan
Ming Gao
Xuejiao Yang
Xia Zhang
Junxun Ma
Guanghai Dai
BMC Cancer, 23
[9] Comparison of efficacy and safety between PD-1 inhibitors and PD-L1 inhibitors plus platinum-etoposide as first-line treatment for extensive-stage small-cell lung cancer: a multicenter, real-world analysis
Wang, Yanrong
Li, Lingling
Hu, Jia
Zhao, Yan
Yan, Huan
Gao, Ming
Yang, Xuejiao
Zhang, Xia
Ma, Junxun
Dai, Guanghai
BMC CANCER, 2023, 23 (01)
[10] Real-world experience with anti-PD-1/PD-L1 monotherapy in patients with non-small cell lung cancer A retrospective Austrian multicenter study
Geiger-Gritsch, Sabine
Olschewski, Horst
Kocher, Florian
Wurm, Robert
Absenger, Gudrun
Flicker, Martin
Hermann, Andre
Heininger, Peter
Fiegl, Michael
Zechmeister, Melanie
Endel, Florian
Wild, Claudia
Pall, Georg
WIENER KLINISCHE WOCHENSCHRIFT, 2021, 133 (21-22) : 1122 - 1130

← 1 2 3 4 5 →